JTE-451 is under clinical development by Orphagen Pharmaceuticals and currently in Phase II for Plaque Psoriasis (Psoriasis Vulgaris). According to GlobalData, Phase II drugs for Plaque Psoriasis (Psoriasis Vulgaris) have a 47% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how JTE-451’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

JTE-451 overview

JTE-451 is under development for the treatment of autoimmune diseases such as plaque psoriasis and allergic diseases. The therapeutic candidate is formulated as a tablet and administered via oral route. It acts by targeting nuclear receptor ROR gamma.

Orphagen Pharmaceuticals overview

Orphagen Pharmaceuticals (Orphagen) operates as a drug development company that discovers and develops small molecules for orphan nuclear receptors. The company’s pipeline products include OR-682, for the treatment of immuno-oncology including ovarian, pancreatic, and liver cancer. It develops antagonists for orphan nuclear receptor steroidogenic factor-1, to treat adrenocortical cancer and Cushing’s syndrome. Orphagen also provides nuclear receptor profiling and screening services. The company has partnership agreement with the companies to discover and develop oral drugs for the treatment of psoriasis and other autoimmune diseases. Orphagen is headquartered in San Diego, California, the US.

For a complete picture of JTE-451’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.